Unlike that study, we directly silenced EphA2 using shRNA in a syngeneic, immunocompetent orthotopic model, providing in vivo mechanistic evidence that EphA2 depletion attenuates tumor growth and apoptosis resistance while suppressing the EphA2/FAK/RhoA axis. This evidence concerns the gene PTK2 and neoplasm.